Evaluation of long-term outcome and prognostic factors of feline squamous cell carcinomas treated with photodynamic therapy using liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine

Flickinger, Irene; Gasymova, Eva; Dietiker-Moretti, Simona; Tichy, Alexander; Bley, Carla Rohrer

doi:10.1177/1098612x17752196

Cited by 8 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several reports exist on PDT use in veterinary medicine, this treatment is not part of the standard treatments for ocular neoplasms [ 107 , 108 , 109 , 110 , 111 , 112 , 113 ]. However, in human medicine, PDT is indicated in treating several eye conditions, which justifies its interest in treating veterinary eye diseases [ 108 ].…”

Section: Treatmentsmentioning

confidence: 99%

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

Guimarães

Cardoso

Tralhão³

et al. 2021

Bioengineering

View full text Add to dashboard Cite

Neoplasms of melanocytic origin are diseases relevant to dogs and cats’ ophthalmic oncology due to their incidence, potential visual loss, and consequent decrease in life quality and expectancy. Despite its non-specific clinical presentation, melanocytic neoplasms can be histologically distinguished in melanocytomas, which present benign characteristics, and malignant melanomas. The diagnosis often occurs in advanced cases, limiting the therapeutic options. Surgery, cryotherapy, radiotherapy, photodynamic therapy (PDT), and laser are currently available therapeutic strategies. As no clinical guidelines are available, the treatment choice is primarily based on the clinician’s preference, proficiency, and the owner’s financial constraints. While surgery is curative in benign lesions, ocular melanomas present a variable response to treatments, besides the potential of tumour recurrences or metastatic disease. This review presents the currently available therapies for ocular melanocytic neoplasms in dogs and cats, describing the therapeutic, indications, and limitations. Additionally, new therapeutics being developed are presented and discussed, as they can improve the current treatment options.

show abstract

Section: Treatmentsmentioning

confidence: 99%

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

Guimarães

Cardoso

Tralhão³

et al. 2021

Bioengineering

View full text Add to dashboard Cite

show abstract

“…It is mainly used to treat early skin tumors in cats and some studies have reported treating urinary tract neoplasia in dogs and equine sarcoids (546). With regard to temoporfin, a study by Flickinger et al (310) investigated the long-term outcome of using Foslip for systemic treatment of feline squamous cell carcinomas. The study (0.15 mg drug kg À1 body weight i.v., 6 h postinjection, illumination with 652 nm diode laser, 0.5 W cm À2 ) showed a very good response rate of 84% and a mean progression-free interval of 35 months.…”

Section: Veterinary Applicationsmentioning

confidence: 99%

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡

Wiehe

Senge

2022

Photochem & Photobiology

View full text Add to dashboard Cite

This review follows the research, development and clinical applications of the photosensitizer 5,10,15,20-tetra(mhydroxyphenyl)chlorin (mTHPC, temoporfin) in photodynamic (cancer) therapy (PDT) and other medical applications. Temoporfin is the active substance in the medicinal product Foscanâ authorized in the EU for the palliative treatment of head and neck cancer. Chemistry, biochemistry and pharmacology, as well as clinical and other applications of temoporfin are addressed, including the extensive work that has been done on formulation development including liposomal formulations. The literature has been covered from 2009 to early 2022, thereby connecting it to the previous extensive review on this photosensitizer published in this journal [Senge, M. O. and J. C. Brandt (2011) Photochem. Photobiol. 87, 1240-1296] which followed its way from initial development to approval and clinical application.

show abstract

“…This outcome illustrated that liposomal PS was safety and efficacy ( 76 ). Scientists ( 77 ) investigated the long-term outcomes and prognostic factors of feline cSCC following the intravenous injection of liposomal phosphorylated mTHPC under irradiation with a 652-nm diode laser, and the overall response rate was 84% (complete remission, 61%; partial remission, 22%) with a mean progression-free interval of 35 months. Woźniak et al.…”

Section: Application Of Nano-pdt In Skin Cancermentioning

confidence: 99%

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

et al. 2022

View full text Add to dashboard Cite

Comprehensive cancer treatments have been widely studied. Traditional treatment methods (e.g., radiotherapy, chemotherapy), despite ablating tumors, inevitably damage normal cells and cause serious complications. Photodynamic therapy (PDT), with its low rate of trauma, accurate targeting, synergism, repeatability, has displayed great advantages in the treatment of tumors. In recent years, nanotech-based PDT has provided a new modality for cancer treatment. Direct modification of PSs by nanotechnology or the delivery of PSs by nanocarriers can improve their targeting, specificity, and PDT efficacy for tumors. In this review, we strive to provide the reader with a comprehensive overview, on various aspects of the types, characteristics, and research progress of photosensitizers and nanomaterials used in PDT. And the application progress and relative limitations of nanotech-PDT in non-melanoma skin cancer and melanoma are also summarized.

show abstract

Evaluation of long-term outcome and prognostic factors of feline squamous cell carcinomas treated with photodynamic therapy using liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine

Abstract: PDT using a systemic photosensitiser leads to excellent long-term tumour control in the majority of cats. However, invasive and large tumours had a clearly inferior outcome, even if treated with the higher-dose intensity. This suggests that advanced lesions are not indications for PDT.

Cited by 8 publications

References 15 publications

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

Contact Info

Product

Resources

About

Evaluation of long-term outcome and prognostic factors of feline squamous cell carcinomas treated with photodynamic therapy using liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine

Abstract: PDT using a systemic photosensitiser leads to excellent long-term tumour control in the majority of cats. However, invasive and large tumours had a clearly inferior outcome, even if treated with the higher-dose intensity. This suggests that advanced lesions are not indications for PDT.

Cited by 8 publications

References 15 publications

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade†‡

Advances in Photodynamic Therapy Based on Nanotechnology and Its Application in Skin Cancer

Contact Info

Product

Resources

About

The Photosensitizer Temoporfin (mTHPC) – Chemical, Pre‐clinical and Clinical Developments in the Last Decade^†^‡